NR4A1 and breast cancer: Importantly, both groups exhibited comparable pCR rates when treated with NACT, aligning with previous studies (11,13,15,43-45) and contrasting sharply with the limited response rates generally seen in hormone-receptor-positive/HER2- BC (46, 47).